Impact of Bulky & Liposomal Secukinumab on Lymphocytes of Psoriatic Patients, to Determine the Improvement in Bioavailability of Secukinumab Nanolipo

Psoriasis is an immune-mediated disease affecting the skin and joints. biologic treatments are often used in moderate to severe cases, administered as a monotherapy or in combination with other treatments. Liposomes are versatile and can enhance drug retention, reducing systemic side effects, and are used for therapy and research. This research study aimed to investigate the Geno toxicity of Secukinumab, an ideal biologic treatment for psoriasis (a human IgG1k antibody, anti-IL17A), in bulk and liposome nanoparticles on the lymphocytes of psoriatic patients in comparison with healthy persons. Geno toxicity of Secukinumab in bulk and liposomal form was evaluated and compared by using the Comet and micronucleus assays. From assays, it was demonstrated that Secukinumab in both forms did not exhibit Geno toxicity and reduced DNA damage following the treatment of psoriatic patient lymphocytes and healthy individual’s lymphocytes with Secukinumab bulk and liposomes format. Secukinumab used (2.1 and 2.8 µg/mL) with two different concentrations, and effectively decreased DNA damage induced by H2O2 in both groups to almost the negative control level. Secukinumab bulk and liposome form markedly reduced the H2O2-induced damage and proficiently diminished its adverse effects both in the Comet (p<0.0001) and micronucleus as-says (p<0.01). Overall, Secukinumab in both forms showed anti-genotoxic and protective effects by expressing its potential to reduce DNA damage produced by oxidative stress and it was observed that it would not induce any further damage in the lymphocytes of healthy individuals and patients.